Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule medicines for central nervous system (CNS) disorders, aiming to address significant unmet needs in neurology and psychiatry [1][2] - The company has a focused portfolio and proprietary research to establish a competitive edge in the CNS therapeutics market [1] Product Pipeline - The lead candidate is RAP-219, targeting focal epilepsy and other CNS indications, with additional programs addressing chronic pain and hearing disorders [3] - Positive results from a phase 2a clinical trial for RAP-219 were reported in September 2025, leading to a share price increase [8] Financial Performance - Rapport Therapeutics reported a net loss of $26.9 million in Q3 2025, but held cash, cash equivalents, and short-term investments totaling $513 million, expected to sustain operations into the second half of 2029 [8] - As of November 14, 2025, shares were priced at $24.37, reflecting a 10.87% increase over the past year, although underperforming the S&P 500 by 1.0 percentage points [3] Investment Activity - Cormorant Asset Management increased its holding in Rapport Therapeutics by purchasing an additional 251,600 shares, raising its total position to 3,192,521 shares valued at $94.82 million [5][6] - This purchase increased Cormorant's stake by approximately $61.38 million, representing 6.54% of its assets under management [4][5]
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?